5 Stocks To Sell According To Billionaire Louis Bacon

2. Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 43

Louis Bacon added 190,000 Moderna, Inc. (NASDAQ:MRNA) shares to his portfolio during the third quarter of 2021, valued at $73.1 million, representing 1.11% of the billionaire’s total 13F securities for the period. In Q4 2021, he discarded his entire stake in the company. Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company developing therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune disorders. 

Piper Sandler analyst Edward Tenthoff believes the FDA’s full approval today of Spikevax “broadly de-risks Moderna’s rich mRNA vaccine pipeline.” He reiterated an Overweight rating on Moderna, Inc. (NASDAQ:MRNA) shares on January 31 with a $348 price target. Moderna shipped 807 million Spikevax doses for revenues of over $17.5 billion in 2021, and has advanced purchase agreements of $18.5 billion in 2022, the analyst told investors in a research note. 

In the fourth quarter of 2021, 43 hedge funds were bullish on Moderna, Inc. (NASDAQ:MRNA), with stakes equaling $3.8 billion, as compared to 49 funds in the quarter earlier, holding stakes worth $7.3 billion in Moderna, Inc. (NASDAQ:MRNA). Billionaire Philippe Laffont’s Coatue Management is a significant Moderna, Inc. (NASDAQ:MRNA) stakeholder, holding over 4 million shares, valued at more than $1 billion.

Here is what Carillon Tower Advisers has to say about Moderna, Inc. (NASDAQ:MRNA) in its Q3 2021 investor letter:

“Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The stock proved to be an impressive contributor once again in the quarter, as investors continue to evaluate the potential for future growth driven primarily by the firm’s revolutionary COVID-19 vaccine. Strong global demand for the vaccine may persist for the foreseeable future in order to maintain immunity as well as provide protection against any additional future variants. The potential for the firm’s mRNA technology to be used in a number of other use cases, specifically influenza, could also provide an additional tailwind for future growth.”